Given that Plexin-B1 is expressed on microglia (24), rather than on lymphocytes (36, 37), it seems reasonable to assume that a therapy based on Plexin-B1 blockade is not expected to carry the risk of progressive multifocal leukoencephalopathy. Here, PLXNB1 is linked to progressive multifocal leukoencephalopathy.